Overview

ATS907 Ph2a Open-Label Dose-ranging Safety and Tolerability in Primary Open Angle Glaucoma (POAG) and Ocular Hypertension (OHT) Subjects

Status:
Completed
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
This single-site, dose-escalation study will evaluate safety and tolerability of increasing concentrations of ATS907 in 12 subjects with Primary Open Angle Glaucoma and/or Ocular Hypertension
Phase:
Phase 2
Details
Lead Sponsor:
Altheos, Inc.